Amleto D`Agostino, Fondazione SDN, 25 Ottobre 2013

Amleto D’Agostino, Fondazione SDN, 25 Ottobre 2013
CAMPANIA BIOSCIENCE: NETWORK IN PROGRESS
Key issues for Campania Bio-community
Extraordinary offer
High quality offer
in terms of
in terms of
knowledge and
facilities and
research
tools (technology
capabilities
platforms)
Strong science
base centres with
a high skilled
workforce
Feeble bioindustrial
development
CAMPANIA BIOSCIENCE: NETWORK IN PROGRESS
Scientific Offer
Extraordinary offer in terms of biology sciences-oriented research institutes/centres


4 Universities
5 National Research Council Institutes and “Anton Dohrn” Zoological Institute of
Naples




3 Biotechnology research networks: BioTekNet; DFM; GEAR
3 No profit bio-consortiums for research: CEINGE, TIGEM and BIOGEM
30.000 square meters of laboratories
60 patents
"BIO" AREA - EMPLOYEES IN R&D IN
"CONVERGENCE" REGIONS
Source: Cineca data (on February 2011) and National Research Council
(CNR)
HEALTH AND BIOTECH - BENCHMARK EMPLOYEES IN
R&D
Source: Cineca data (on February 2011) and National Research Council
(CNR)
Regioni analizzate
HEALTH AND BIOTECH - SCIENTIFIC PUBLICATIONS
Campania
Sicilia
Puglia
Calabria
0
10
20
30
40
50
60
Numero scienziati presenti nella Top Italian Scientists
Source: Cineca data (on February 2011) and National Research Council
(CNR)
NUMBER OF BIOTECH COMPANY, TURNOVER,
INVESTMENTS IN R&D AND R&D EMPLOYEES
COMPANIES IN CAMPANIA BIO-COMMUNITY
Campania Region currently hosts pretty remarkable bio-companies
such as HARDIS belonging to KEDRION group; ALTERGON
ITALIA
(linked
NOVARTIS;
to
the
Swiss
DSM
and
the
company
newborn
IBSA);
OKAIROS;
company
ARTERRA
BIOSCIENCE. In spite of its outstanding industrial growth for
southern Italy, the number of the industrial companies is far behind
the
strong
competences
presence
of high
level
research
centers
and
MAIN COMPETENCES
Pharmacogenomics
Bioinformatics
Industrial Biotechnologies
Gene expression and proteomics
Nutraceuticals, cosmeceuticals
and functional foods
Bioremediation and
biodegradation
Molecular diagnostics
Gene therapy
MAIN CHALLENGES
To finalize financial efforts by a medium-long-term strategic approach
To improve results and Intellectual Property exploitation
To enhance technology transfer
To support transnational researches and projects
FIRST CLUSTERING STEP: THE IMPLEMENTATION OF
REGIONAL NETWORK
14.12.2007
Centro Regionale di Competenza
in Biotecnologie Industriali
14.12.2007
Beginning 2008
SECOND CLUSTERING STEP: THE IMPLEMENTATION
OF A CLUSTER
Pharma Industries
Diagnostic Industries
Nutraceutis and Food
Industries
STATE OF THE ART
Feasibility Study presentation to build the
22/03/2011
• Cluster
Presentazione
studio di fattibilità
Campania Bioscience
23/04/2012
Study of Campania
approval
by the
• Feasibility
Approvazione
dello Bioscience
studio di
fattibilità
Italian
MinistryBioscience
for Universities
and Research
Campania
da parte
del MIUR
07/08/2012
of Frameworkdi
Programme
Agreement
MIUR• Conclusion
Stipula Accordo
Programma
Quadro
Campania
MIUR –Region
Regione Campania
•
14/02/2013
Establishment of Campania Bioscience SCaRL ( Ltd.
Company)
Next step (November 2013): Evaluation of the executive project
LEGAL ENTITY OF THE CLUSTER
Legal name
Campania Bioscience SCaRL
Legal status
Società Consortile a Responsabilità Limitata
Members
Research organizations
Companies
Scientific Parks
Shares
44 % Research organizations
44 % Companies
12 % Scientific Parks
Object
No-profit
Capital
1,7 Millions Euros
CAMPANIA BIOSCIENCE’S Shareholders
48 companies:
N. 8 Research organizations
13 big enterprises
11 medium enterprises
24 small enterprises
THE INDUSTRIAL SHAREHOLDERS
THE INDUSTRIAL SHAREHOLDERS
THE INDUSTRIAL SHAREHOLDERS
UNIVERSITIES, RESEARCH ORGANIZATIONS AND
SCIENTIFIC PARKS
GOVERNANCE OF CAMPANIA BIOSCIENCE
Shareholders’ Assembly
Companies
Audit Committee
Research
3
Confindustria
TT Structures
organizations
1
1
3
Board od Directors
Chairman
General Manager
GTT M Monitoring
executive projects
GTT 1
GTT 2
Technology Training and transfer, development of Networking. human Dissemination
resources
GTT 3
Nutraceutical
and Cosmeceutical
GTT 4
Diagnostic and Biomedical
Board of GTT 5
New Therapies
management
GTT M
GTT 1
GTT 2
Franco
Salvatore
(Ceinge)
Giovannangelo
Oriani (Ceinge)
Francesco
Rossi (SUN)
Mario De Rosa
(SUN)
Chiara Schiraldi
(SUN)
Paolo Netti (FII)
Tommaso
Russo (FII)
Vincenzo
Pavone (FII)
Francesco
Beguinot (FII)
Fabrizio
Ferrando
(Esaote)
Roberto Vona
(FII)
Mario Sorrentino
(SUN)
Alessandro
Indiveri
(Technapoli)
Pino Manco
(CNR)
Roberto
Tagliaferri
(Unisa)
Alfonsina
Migliozzi
(Mataluni)
Stefania Spinelli
(PST SA)
Andrea Di Maso
(Biogem)
Gianluca Di Brina
(Engineering)
Concetta D’Orio
(BioTekNet)
Vincenzo
Maggioni (SUN)
Roberto Parente
(Unisa)
Giuseppe Zollo
(FII)
Giovanni De
Simone (FII)
Maria Rosaria
Napolitano
(Unisannio)
Gabriella
Minchiotti (CNR)
Domenico
Gambacorta
(Biogem)
Paola Mazzocca
(TechnapolI)
Isabella
Colamarco (PST
SA)
Achille Masturzo
(BioTekNet)
GTT 3
GTT 4
Gabriele
Riccardi (FII)
Ettore
Novellino (FII)
Chiara Schiraldi
Elena De Marco
(Mataluni)
Agostino
Casapullo
Barbara
Nicolaus (CNR)
Luigi Fontana
(UNISA)
Pasquale Vito
(Unisannio)
Salvatore
Riccio (UNISA)
Andrea Giori
(IBSA)
Alberto Luini
(CNR)
Alessandro
Nencioni
(Esaote)
Giuseppe
Castaldo (FII)
Marco Salvatore
(FII)
Lucia Altucci
(SUN)
Vincenzo Nigro
(SUN)
Raffaele Riccio
(UNISA)
Francesco
Mancini
(Unisannio)
Mario De Felice
(FII)
Massimiliano
Minale (Damor)
GTT 5
Fortunato
Ciardiello (SUN)
Stefania Amorosi
(Altergon)
Gianfranco Di
Renzo (FII)
Lucio Pastore
(FII)
Liberato Berrino
(SUN)
Aldo Pinto
(UNISA)
Vittorio de
Franciscis (CNR)
Claudio Pisano
(Biogem)
Francesco Izzo
(Pascale)
Anna Tortiglione
(Damor)
LINE 1 – R&D ACTIVITIES OF THE CLUSTER
Line 1 – Infrastructures and Industrial Research
Enforce and integrate the R&D infrastructures
(companies
and
research
organizations)
and
implement industrial research activities in the
following three thematic areas:
1) Development and Production of nutraceuticals and
cosmeceuticals
2)
Diagnostics,
biosensors
and
technologies for biomedical industry
3) New therapies
innovative
CAMPANIA BIOSCIENCE: R&D PROJECTS
1. Strategies for the recovery of bioactive compounds from waste in the food
industry
2. Design, development and production of functional foods and / or enriched
3. Development and testing of molecules with nutraceutical and cosmeceutical
properties
4. New strategies for medical and molecular diagnosis and for food traceability
and monitoring
5. New strategies for medical and molecular diagnosis and for food traceability
and monitoring
6. Smart materials and new devices for biomedical applications
7. Preclinical development of new therapies and innovative strategies for the
production of molecules with pharmacological activity
8. Preclinical and phase o and 1 clinical evaluation of molecules with
nutraceutical, cosmeceutical and pharmaceutical properties and/or new
indications for already approved compounds
ECONOMIC OPPORTUNITIES
2008 European data on Health market (including nutraceuticals, diagnostics in vitro
and imaging and new therapies) was US$ 208.91 billions. Growth estimation per
year is more than 6% from 2009 to 2014.
HEALTH
CAGR
2009-2014
EU market 2008
(billions $)
Nutraceuticals
4,3%
60,33
In vitro
diagnostics
and imaging
5,3%
16,10
New therapies
10%
132,48
Total
208,91
LINE 2 AND 3 – TRAINING AND CLUSTER START-UP
Line 2 – Human Resources Valorisation
Training activities of technical profiles in line with the
industrial research projects of the Cluster and other
activities to attract young talents
Line 3 – Start-up of the Cluster and activities of marketing,
internationalisation and technology transfer
Management and technology transfer activities supporting
newcos and start-up
PRIORITIES OF HORIZON 2020 AND CLUSTER VISION
Priorities of Horizon 2020: Demografic change, wellbeing, food security
Technology objectives of Campania Bioscience Cluster:
1) Nutraceutical development
2) Growth and children products
3) Functional food
4) Innovative cosmeceuticals
5) Food genetic-molecular tracking
PRIORITIES OF HORIZON 2020 AND CLUSTER VISION
Priorities of Horizon 2020: Health, biotechnology
and advanced manifacturing
Technology objective of Campania Bioscience Cluster:
1) New therapies
2) Pharma treatment customization
3) Systems for molecular and imaging diagnostics
4) Biomedical technologies
5) Innovative bioprocesse
…….To Europe
Ehealthnet (APP)
Sorriso (APP)
Il Cluster campano Salute,
Biotecnologie e Agroalimentare
(Contratto di Rete)
M2Q (APP)
Biocam (APP)
Marea (APP)
Alisei
Il Cluster tecnologico
nazionale delle
Scienze della Vita
Le Bioregion
europee
Dr Amleto D’Agostino, General Manager Campania Bioscience
Tel +390815667678
Mail [email protected]